Guest Blogger: Mary Jo Kurth, Business Development Manager at Randox, reviews The Healthcare Innovation Expo
Today Mary Jo Kurth, Business Development Manager at Randox, jumps in the blogging seat to share her thoughts on the Healthcare Innovation Expo.
I attended Healthcare Innovation Expo last week on behalf of Randox Laboratories Ltd. The presentations were interesting and there was good discussion about innovation in the NHS and how to introduce new innovative technologies into the NHS. Indeed many of the individuals that attended our stand were involved in translational research. This is an exciting time for innovative companies like Randox.
We exhibited our MultiStat Instrument which is a point of care instrument designed to be used with our Cardiac Array. The Cardiac Array produces results for Heart-fatty acid binding-protein (H-FABP), Troponin I and CK-MB from a single patient sample within 30 minutes in the ED, thereby improving TAT when compared with the central laboratory. With a 98% negative predictive value for MI at 3-6 hours post chest pain onset, the combination of H-FABP and Troponin I has the potential to allow for earlier discharge of non cardiac patients currently being unnecessarily admitted for a 12 hour test.
The intended use of the H-FABP assay is for the early rule out of MI and the risk stratification of low to medium risk ACS patients in the absence of necrosis. Unlike troponin, H-FABP is released without the presence of necrosis, allowing for the detection of troponin negative patients who are nevertheless at significant and proven risk of increased mortality. A fully quantitative H-FABP assay allows for the risk stratification of these high risk patients who currently either slip through the net or are considered to be of a lower priority.
This technology was also detailed on the QIPP innovation wall and in BIVDA’s “The difference diagnostics can make” pack which was available on the BIVDA stand.
Randox also exhibited our STI Array. The STI Array enables 10 pathogens to be tested for simultaneously in one patient sample in the central laboratory. Results are obtained in 4 hours as opposed to >2 days using current techniques. Savings are made through the correct identification of pathogens and correct treatment, reduced misuse of antibiotics and reduced lab running costs (overheads, staff, and equipment).
Dr Mary Jo Kurth
Business Development Manager, Randox